Company: IMNN
Filing Date: 2025-05-13
Form Type: S-1/A
Source: 0001641172-25-009814
Chunk: 15

Company: Imunon, Inc.
Filing Date: 2025-05-13
Form: S-1/A
Chunk 15
---
 full. For each pre-funded warrant we sell, the number of shares of Common Stock we are offering 
 will be decreased on a one-for-one basis. This prospectus also relates to the offering of the shares of Common Stock issuable upon          
 exercise of the pre-funded warrants. For more information regarding the pre-funded warrants, you should carefully read the section titled   
 “Description of Securities We Are Offering” in this prospectus.                                                                             |
| Common                                     
 warrants offered by us in this offering    |     | We                                                                                                                                          
 are issuing to purchasers of shares of our Common Stock and/or pre-funded warrants in this offering a common warrant to purchase            
 one share of our Common Stock for each share and/or pre-funded warrant purchased in this offering. The shares of Common Stock or            
 pre-funded warrants, respectively, and common warrants are immediately separable and will be issued separately in this offering,            
 but must initially be purchased together in this offering. The common warrants are exercisable beginning                                    
 on the Initial Exercise Date, have an assumed exercise price equal to $1.60, (equal to 200% of the assumed combined public                  
 offering price per share of Common Stock and accompanying common warrant), and will expire two and one-half (2.5) years after the           
 Initial Exercise Date. Holders of the common warrants may effect an “alternative cashless exercise” at any time while                       
 the common warrants are outstanding following the Initial Exercise Date. Under the alternative cashless exercise option, a holder           
 of a common warrant has the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate        
 number of shares of Common Stock that would be issuable upon a cash rather than a cashless exercise of the common warrant and (ii)          
 3.0. Accordingly, it is highly unlikely that a holder of the common warrants would wish to pay an exercise price in cash to receive         
 one share of Common Stock when they could instead choose the alternative cashless exercise option and pay no cash to receive three          
 shares of Common Stock. As a result, we will likely not receive any additional funds and do not expect to receive any additional            
 funds upon the exercise of the common warrants. In addition, on the Adjustment Date, the exercise price of the common warrants will         
 be reduced to the greater of the Floor Price and the lowest daily dollar volume-weighted average price during the period beginning          
 two full trading days prior to the Adjustment Date and ending on the 10th trading day after the Adjustment Date. Upon